IP Library Granted Patent US 9,649,321
Granted Patent B2
US 9,649,321 · App. 14/942,926 · Granted May 16, 2017

Phosphonate compounds

Inventors: Karl Y. Hostetler (Del Mar, CA); James R. Beadle (San Diego, CA)
Assignee: The Regents of the University of California
A61K31/675C07F9/3873C07F9/404C07F9/405C07F9/48C07F9/5728C07F9/65121C07F9/65583C07F9/65616C07H19/04C07H19/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,649,321
App. No.
14/942,926
Granted
May 16, 2017
Kind
B2
Abstract

The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.

Claims (17)

1. A pharmaceutical composition comprising an effective amount of a compound of Formula I:

or a pharmaceutically acceptable salt thereof

and a pharmaceutically acceptable carrier.

2. A method of treating cytomegalovirus comprising administering to a subject in need thereof the pharmaceutical composition of claim 1 .

3. The pharmaceutical composition of claim 1 , wherein the compound of Formula I is:

or a pharmaceutically acceptable salt thereof.

4. A method of treating cytomegalovirus comprising administering to a subject in need thereof the pharmaceutical composition of claim 3 .

5. A pharmaceutical composition comprising a compound of the Formula II:

wherein M + is Na + , Li + , K + , Ca 2+ , Mg 2+ or NR a R b R c R d + , wherein R a , R b , R c and R d are each independently hydrogen or C 1 -C 5 alkyl.

6. A method of treating cytomegalovirus comprising administering to a subject in need thereof the pharmaceutical composition of claim 5 .

7. The pharmaceutical composition of claim 5 , wherein the compound of Formula II is:

wherein M + is Na + , Li + , K + , Ca 2+ , Mg 2+ or NR a R b R c R d + , wherein R a , R b , R c and R d are each independently hydrogen or C 1 -C 5 alkyl.

8. A method of treating cytomegalovirus comprising administering to a subject in need thereof the pharmaceutical composition of claim 7 .

9. The pharmaceutical composition of claim 1 , further comprising one or more components selected from the group consisting of preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorings, buffers, coating agents, antioxidants, diluents, and combinations thereof.

10. The pharmaceutical composition of claim 1 in the form of a tablet or capsule for oral administration.

11. The composition of claim 10 in the form of a tablet further comprising an excipient selected from the group consisting of lactose, maize starch, talc, stearic acid and salts thereof.

12. The composition of claim 10 in the form of a capsule further comprising an excipient selected from the group consisting of vegetable oil, wax, fat, semisolid or liquid polyols and combinations thereof.

Assignments (1)
CONFIRMATORY LICENSE Recorded Dec 13, 2018
From: UNIVERSITY OF CALIFORNIA, SAN DIEGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 047819/0635 →
Continuity (14)
Continuation 14527156 · Oct 29, 2014
Division 14059365 · Oct 21, 2013
Division 13645105 · Oct 4, 2012
Continuation 13220548 · Aug 29, 2011
Continuation 12701410 · Feb 5, 2010
Continuation 11925309 · Oct 26, 2007
Continuation 11715604 · Mar 7, 2007
Continuation 11506292 · Aug 17, 2006
Continuation 11100882 · Apr 6, 2005
Continuation 10759345 · Jan 15, 2004
Continuation 10148374
Provisional Application 60205719 · May 19, 2000
Provisional Application 60168813 · Dec 3, 1999
Related Publication 20160067268A1 · Mar 10, 2016